These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24397608)

  • 21. Ryanodine-receptor inhibition by dantrolene effectively suppresses ventricular arrhythmias in an ex vivo model of long-QT syndrome.
    Frommeyer G; Krawczyk J; Ellermann C; Bögeholz N; Kochhäuser S; Dechering DG; Fehr M; Eckardt L
    J Cardiovasc Electrophysiol; 2018 Mar; 29(3):471-476. PubMed ID: 29314443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenomics and acquired long QT syndrome.
    Aerssens J; Paulussen AD
    Pharmacogenomics; 2005 Apr; 6(3):259-70. PubMed ID: 16013957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
    Eckardt L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An update on risk factors for drug-induced arrhythmias.
    Vlachos K; Georgopoulos S; Efremidis M; Sideris A; Letsas KP
    Expert Rev Clin Pharmacol; 2016; 9(1):117-27. PubMed ID: 26460585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Molecular genetics of the long QT syndrome: clinical aspects].
    Sepp R; Csanády M
    Orv Hetil; 1999 Nov; 140(47):2633-8. PubMed ID: 10613047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implications of anesthesia in children with long QT syndrome.
    Nathan AT; Berkowitz DH; Montenegro LM; Nicolson SC; Vetter VL; Jobes DR
    Anesth Analg; 2011 May; 112(5):1163-8. PubMed ID: 21346158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias.
    Cubeddu LX
    Curr Cardiol Rev; 2016; 12(2):141-54. PubMed ID: 26926294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular biology and cellular mechanisms of Brugada and long QT syndromes in infants and young children.
    Antzelevitch C
    J Electrocardiol; 2001; 34 Suppl():177-81. PubMed ID: 11781953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care.
    Roden DM; Woosley RL; Primm RK
    Am Heart J; 1986 Jun; 111(6):1088-93. PubMed ID: 3716982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval.
    Lorberbaum T; Sampson KJ; Woosley RL; Kass RS; Tatonetti NP
    Drug Saf; 2016 May; 39(5):433-41. PubMed ID: 26860921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions.
    Smithburger PL; Seybert AL; Armahizer MJ; Kane-Gill SL
    Expert Opin Drug Saf; 2010 Sep; 9(5):699-712. PubMed ID: 20377471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antipsychotic-induced sudden cardiac death: examination of an atypical reaction.
    Killeen MJ
    Expert Opin Drug Saf; 2009 May; 8(3):249-52. PubMed ID: 19505259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-induced life-threatening arrhythmias and sudden cardiac death: A clinical perspective of long QT, short QT and Brugada syndromes.
    Ramalho D; Freitas J
    Rev Port Cardiol (Engl Ed); 2018 May; 37(5):435-446. PubMed ID: 29636202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives.
    Kannankeril PJ; Roden DM; Norris KJ; Whalen SP; George AL; Murray KT
    Heart Rhythm; 2005 Feb; 2(2):134-40. PubMed ID: 15851285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
    Singh BN; Wadhani N
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proarrhythmic actions of antiarrhythmic drugs: a review.
    Campbell TJ
    Aust N Z J Med; 1990 Jun; 20(3):275-82. PubMed ID: 2196873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Failure of antiarrhythmia agents and understanding the phenomenon of proarrhythmia].
    Semrád B
    Vnitr Lek; 2003 Sep; 49(9):700-6. PubMed ID: 14584417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural and functional basis for the long QT syndrome: relevance to veterinary patients.
    Finley MR; Lillich JD; Gilmour RF; Freeman LC
    J Vet Intern Med; 2003; 17(4):473-88. PubMed ID: 12892298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.